NCT04425018 2025-11-18MARGOTDana-Farber Cancer InstitutePhase 2 Active not recruiting174 enrolled 19 charts
NCT01828021 2025-03-13Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerMacroGenicsPhase 2 Completed25 enrolled 8 charts